Andre C. Kalil, MD; Josh Levitsky, MD; Elizabeth Lyden, MS; Julie Stoner, PhD; Alison G. Freifeld, MD
Acknowledgments: The authors thank Elaine Litton for providing outstanding administrative support and Patricia A. Kalil for critical review of the manuscript.
Grant Support: None.
Potential Financial Conflicts of Interest: Consultancies: A.G. Freifeld (Enzon); Honoraria: A.G. Freifeld (Pfizer Inc., Enzon, Merck & Co. Inc.); Grants received: A.G. Freifeld (Ortho-McNeil); Grants pending: A.G. Freifeld (Astellas).
Requests for Single Reprints: Andre C. Kalil, MD, University of Nebraska Medical Center, 985400 Nebraska Medical Center, Omaha, NE 68198-5400; e-mail, email@example.com.
Current Author Addresses: Drs. Kalil and Freifeld: University of Nebraska Medical Center, 985400 Nebraska Medical Center, Omaha, NE 68198-5400.
Dr. Levitsky: Northwestern Memorial Hospital, 303 East Chicago Avenue, Chicago, IL 60611.
Ms. Lyden and Dr. Stoner: University of Nebraska Medical Center, 985350 Nebraska Medical Center, Omaha, NE 68198-4350.
Author Contributions: Conception and design: A.C. Kalil. Analysis and interpretation of the data: A.C. Kalil, J. Levitsky, E. Lyden, J. Stoner, A.G. Freifeld. Drafting of the article: A.C. Kalil, E. Lyden, J. Stoner, A.G. Freifeld. Critical revision of the article for important intellectual content: A.C. Kalil, J. Levitsky, E. Lyden, J. Stoner, A.G. Freifeld.Final approval of the article: A.C. Kalil, J. Levitsky, E. Lyden, J. Stoner, A.G. Freifeld. Statistical expertise: E. Lyden, J. Stoner. Collection and assembly of data: A.C. Kalil, J. Levitsky.
Cytomegalovirus (CMV), the most common opportunistic viral infection in solid organ transplant recipients, is associated with substantial morbidity and mortality.
To assess the efficacy of universal prophylaxis and preemptive approaches in preventing CMV organ disease and other complications in solid organ transplant recipients.
Using no language restrictions, the authors searched the following databases from their inception through May 2005: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Evidence-Based Medicine. The authors also reviewed abstracts from scientific meetings and contacted experts and pharmaceutical companies.
Randomized, controlled trials that evaluated antiviral strategies for preventing CMV and associated complications in solid organ transplant recipients were selected.
Two reviewers independently extracted and assessed the data.
The authors found 17 trials involving 1980 patients. Compared with placebo or no therapy, both universal prophylaxis (odds ratio [OR], 0.20 [95% CI, 0.13 to 0.31]) and preemptive strategies (OR, 0.28 [CI, 0.11 to 0.69]) reduced CMV organ disease. However, only universal prophylaxis seemingly reduced CMV organ disease in subgroups of patients at highest risk (donors with positive CMV serostatus and recipients with negative CMV serostatus and induction with antibodies). Both strategies reduced the rate of allograft rejection. Only universal prophylaxis statistically significantly reduced bacterial and fungal infections (OR, 0.49 [CI, 0.36 to 0.67]) and death (OR, 0.62 [CI, 0.40 to 0.96]). Both acyclovir and ganciclovir statistically significantly prevented CMV organ disease in the universal prophylaxis trials.
Studies were of modest size, and few studies assessed all outcomes. Studies did not always provide data that discriminated between CMV organ disease and CMV syndrome or data about the timing of CMV organ disease.
Universal prophylaxis and preemptive strategies are beneficial in preventing CMV organ disease in solid organ transplant recipients. Both strategies are associated with a reduction in allograft rejection, but current data suggest that only universal prophylaxis reduces bacterial and fungal infections and death. Acyclovir and ganciclovir are both effective for universal prophylaxis.
Learn more about subscription options.
Register Now for a free account.
Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. Ann Intern Med. 2005;143:870–880. doi: 10.7326/0003-4819-143-12-200512200-00005
Download citation file:
Published: Ann Intern Med. 2005;143(12):870-880.
Infectious Disease, Nephrology, Pulmonary/Critical Care, Renal Replacement Therapy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only